Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Mitomycin 11Gemcitabine 7BCG Vaccine 4Imiquimod 2Administration, Intravesical 2viscum album peptide 1pemigatinib 1pembrolizumab 1erdafitinib 1dodecyl maltoside 1Water 1VPM1002 recombinant BCG vaccine 1VB4-845 1Therapeutics 1Photochemotherapy 1Neoadjuvant Therapy 1Interferon-alpha 1Hyaluronic Acid 1High-Intensity Interval Training 1Gels 1Ethacrynic Acid 1Epirubicin 1Educational Status 1Doxorubicin 1Docetaxel 1Dihematoporphyrin Ether 1Cystoscopy 1Celecoxib 1BCG Connaught 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Non-Muscle Invasive Bladder Neoplasms × VB4-845 × Clear all
NCT02449239 2023-07-24

VISTA

Sesen Bio, Inc.

Phase 3 Completed
133 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡